These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34375802)

  • 1. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Auvin S; Damera V; Martin M; Holland R; Simontacchi K; Saich A
    Epilepsy Behav; 2021 Oct; 123():108239. PubMed ID: 34375802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and Caregiver Health State Utilities in Lennox-Gastaut Syndrome and Dravet Syndrome.
    Lo SH; Lloyd A; Marshall J; Vyas K
    Clin Ther; 2021 Nov; 43(11):1861-1876.e16. PubMed ID: 34774333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey.
    Berg AT; Dixon-Salazar T; Meskis MA; Danese SR; Le NMD; Perry MS
    Epilepsy Res; 2024 Feb; 200():107280. PubMed ID: 38183688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
    Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
    Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA).
    Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D
    Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea.
    Koo CM; Kim SH; Lee JS; Park BJ; Lee HK; Kim HD; Kang HC
    J Korean Med Sci; 2020 Dec; 35(50):e427. PubMed ID: 33372424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
    Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
    Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
    Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
    Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
    Frampton JE
    Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy.
    Villanueva V; García-Ron A; Smeyers P; Arias E; Soto V; García-Peñas JJ; González-Alguacil E; Sayas D; Serrano-Castro P; Garces M; Hampel K; Tomás M; Lara J; de Toledo M; Barceló I; Aledo-Serrano A; Gil-Nagel A; Iacampo L; Falip M; Saiz-Diaz RA; Gómez-Ibañez A; Sopelana D; Sanchez-Larsen A; López-González FJ
    Epilepsy Behav; 2022 Dec; 137(Pt A):108958. PubMed ID: 36327646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabidiol use in patients with Dravet syndrome and Lennox-Gastaut syndrome: experts' opinions using a nominal group technique (NGT) approach.
    Bonanni P; Ragona F; Fusco C; Gambardella A; Operto FF; Parmeggiani L; Sartori S; Specchio N
    Expert Opin Pharmacother; 2023 Apr; 24(5):655-663. PubMed ID: 37021712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice.
    Wirrell EC; Lagae L; Scheffer IE; Cross JH; Specchio N; Strzelczyk A
    Epilepsia Open; 2024 Oct; 9(5):1643-1657. PubMed ID: 38962968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emotional burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy: A qualitative study in Japan.
    LoPresti M; Igarashi A; Sonohara Y; Bowditch S
    Epilepsy Behav; 2024 Sep; 158():109932. PubMed ID: 39029305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative cross-sectional study of the burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy in Japan.
    LoPresti M; Igarashi A; Sonohara Y; Bowditch S
    Epilepsy Behav; 2024 May; 154():109741. PubMed ID: 38555725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Villanueva V; Carreño-Martínez M; Gil Nagel-Rein A; López-González FJ
    Rev Neurol; 2021 Apr; 72(S01):S1-S10. PubMed ID: 33908026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
    Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
    Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
    Wechsler RT; Burdette DE; Gidal BE; Hyslop A; McGoldrick PE; Thiele EA; Valeriano J
    Epilepsia Open; 2024 Oct; 9(5):1632-1642. PubMed ID: 39007525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.